Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yaoming Gu

Interventional Pain Medicine Richmond, VA Medical Doctor

NPI 1265478184 CMS profile 193753

1630 Wilkes Ridge Pkwy Ste 203, Richmond, VA 23233

Open in the dashboard

General payments

$13,262

577 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yaoming Gu of Richmond, VA is reported in the CMS Open Payments database as having received $13,262 across 577 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,794 70
2024 General $2,479 83
2023 General $2,153 116
2022 General $2,064 90
2021 General $1,554 71
2020 General $1,003 57
2019 General $2,215 90

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yaoming Gu
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Yaoming Gu were reported at $1,794. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Yaoming Gu Interventional Pain Medicine median Middle half National median
2019 $2,215 $684 $216–$2,079 $163
2020 $1,003 $382 $122–$1,109 $114
2021 $1,554 $552 $167–$1,554 $132
2022 $2,064 $605 $187–$1,924 $149
2023 $2,153 $671 $195–$1,915 $160
2024 $2,479 $684 $206–$1,837 $164
2025 $1,794 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Collegium Pharmaceutical, Inc. $1,583 92 payments
  2. SI-BONE, Inc. $1,017 11 payments
  3. AbbVie, Inc. $792 49 payments
  4. Vertos Medical, Inc. $738 5 payments
  5. Boston Scientific Corporation $728 49 payments
  6. Medtronic, Inc. $502 15 payments
  7. Abbott Laboratories $487 21 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $448 26 payments
  9. Pfizer Inc. $425 23 payments
  10. Averitas Pharma Inc. $401 14 payments
  11. Other $6,141 272 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,060 573 payments
  2. Travel and Lodging $1,201 4 payments
Products named General payments · program years 2019–2025
  1. XTAMPZA $1,255 76 payments
  2. IFUSE IMPLANT SYSTEM $849 4 payments
  3. Qutenza $730 28 payments
  4. WaveWriter Alpha Prime 16 $533 38 payments
  5. UBRELVY $462 29 payments
  6. mild Device Kit $416 3 payments
  7. INTELLIS ADAPTIVESTIM $396 10 payments
  8. RELISTOR $373 22 payments
  9. NURTEC ODT $339 18 payments
  10. BELBUCA $327 16 payments
  11. Other $9,010 413 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

4,020

Median for Interventional Pain Management: 1,220

Drug cost

$86,228

Median for Interventional Pain Management: $39,344

Branded share of claims

36.3%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 660 $15,793
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 615 $10,512
Lidocaine Generic 56 $9,524
Oxycodone Hcl Generic 406 $7,549
Ztlido Lidocaine Brand 11 $7,106
Xtampza Er Oxycodone Myristate Brand 13 $6,263
Gabapentin Generic 481 $4,784
Tramadol Hcl Er Tramadol Hcl Brand 21 $3,553
Pregabalin Generic 157 $3,303
Cyclobenzaprine Hcl Generic 284 $1,807

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$411,923

Of which drugs: $13,374

Medicare patients

469

Average age 72

Services billed

6,992

328 women, 141 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 38%
Diabetes 33%
Osteoporosis 30%
Ischemic heart disease 24%
Chronic kidney disease 24%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 Office 15 92 $8,658
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 21 43 $219
Injection, methylprednisolone acetate, 1 mg J1010 Office 37 1,921 $170
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 43 442 $36

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BELBUCA
  • Collegium Pharmaceutical, Inc. $152
$152 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $136
$136 13 —
Qutenza
  • Averitas Pharma Inc. $111
$111 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $95
$95 — —
NURTEC ODT
  • PFIZER INC. $75
$75 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

577 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record